Grace Therapeutics, Inc.
Company Stats
- Market Cap
- $45.2M
- as of Sep 30, 2026
- Shares Outstanding
- 21.0M
- Free Float
- 40.1%
Income Statement
- Operating Income
- -$11.1M
- Net Income
- -$7.8M
- EBITDA
- -$11.1M
Balance Sheet
- Cash & Equivalents
- $17.0M
Returns & Capital
- SBC, 3Y Avg
- $813,667
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2022 | $0 | — | — |
Annual filing data through FY ended March 31, 2026; shares and float as of October 11, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
XBiotech Leads Buying Intensity; Gold.com Draws $3.93 Million